NCT06143098

Brief Summary

This study is asses the hematological changes in children with chronic kidney disease stage 3 to 5 including

  • Complete blood picture
  • Coagulation profile (PT, PC, PTT)
  • Iron study

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
102

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2024

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 14, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 22, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

March 1, 2024

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2025

Completed
Last Updated

February 20, 2024

Status Verified

February 1, 2024

Enrollment Period

Same day

First QC Date

November 14, 2023

Last Update Submit

February 16, 2024

Conditions

Keywords

CBC in CKDIron profile in CKDCoagulation profile in CKD

Outcome Measures

Primary Outcomes (3)

  • descreption and observation in Complete blood count parameters in children with CKD

    asses changes in Complete blood count parameter in children with chronic kidney disease stage 3 to 5

    baseline

  • descreption and observation in iron profile in children with CKD

    asses changes in serum ferritin ,serum iron, Trans ferritin saturation and Total iron binding capacity in children with chronic kidney disease stage 3 to 5

    baseline

  • descreption and observation in coagulation profile in children with CKD

    asses changes in prothrombin time, prothrombin concentration, partial thromboplastin time,and international normalized ratio in children with chronic kidney disease stage 3 to 5

    baseline

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Childen aged 1:18 years with chronic kidney disease stage 3 to 5 (estimated glomerular filteration rate \>60 ml/min per 1.73 m2).

You may qualify if:

  • Childen aged 1:18 years with chronic kidney disease stage 3 to 5 (estimated glomerular filteration rate \>60 ml/min per 1.73 m2).

You may not qualify if:

  • Children \>1year.
  • Children with chronic kidney disease in stage 1 and 2.
  • Children with liver disease.
  • Children known blood disorder rather than anemia.
  • Children with malignancy.
  • Children with recent bleeding tendancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Hashmi MF, Shaikh H, Rout P. Anemia of Chronic Kidney Disease. 2024 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK539871/

    PMID: 30969693BACKGROUND

MeSH Terms

Conditions

Hematologic Diseases

Condition Hierarchy (Ancestors)

Hemic and Lymphatic Diseases

Study Officials

  • Kotb Abbass, professor

    Assiut University

    STUDY DIRECTOR
  • Asmaa Ahmed, lecture

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

November 14, 2023

First Posted

November 22, 2023

Study Start

March 1, 2024

Primary Completion

March 1, 2024

Study Completion

January 31, 2025

Last Updated

February 20, 2024

Record last verified: 2024-02